Many studies have suggested a link between long-term PPI treatment and hypomagnesaemia, though none of them investigated the short-term exposure in high-risk patients. We sought to investigate this issue in 90 critically ill patients. We assessed serum Mg concentrations, necessity of Mg supplementation, PPI dose, duration of PPI therapy and route of administration. In multiple analysis we found...

n abnormally prolongedQT interval is associated with an increased risk of sudden cardiac death. ASome professional bodies recommend national population-based screening programs to detect QT prolongation. Familial long QT syndrome (LQTS) may remain undetected because of misdiagnosis (eg, as a seizure disorder) or through failure to measure the QT interval correctly. Psychiatrists fear the QT pro...

Imatinib mesylate is an anticancer agent that selectively inhibits protein kinases involved in the pathophysiology of cancer. It is now the first-line therapy for patients with chronic myeloid leukaemia (CML) and is generally well tolerated. Here, we describe a case of a patient receiving imatinib for CML. The patient developed renal failure accompanied by severe hypophosphataemia, hypokalaemia...

BACKGROUND Refeeding syndrome (RFS) is a common, yet underappreciated, constellation of electrolyte derangements that typically occurs in acutely ill, malnourished hospitalised patients who are administered glucose solutions or other forms of intravenous or enteral nutrition. DISCUSSION The hallmark of RFS is hypophosphataemia, but hypokalaemia and hypomagnesaemia are also common. Patients wi...

BACKGROUND TRPM6 gene mutation has been reported to cause hypomagnesemia with secondary hypocalcemia (HSH). However, the genotype-phenotype correlation for TRPM6 gene mutations has not been clarified. OBJECTIVE To elucidate the factors underlying the severe neurological complications in HSH and evaluate the potential association between the location of TRPM6 gene mutations and clinical data o...

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal-recessive renal tubular disorder characterized by excessive urinary losses of magnesium and calcium, bilateral nephrocalcinosis and progressive chronic renal failure. Presentation with FHHNC symptoms generally occurs early in childhood or before adolescence. At present, the only therapeutic option is suppo...